Trial ID or NCT#
NCT01364727
Status
Purpose
A research study of the drug amrubicin in patients with cancer of the thymus (thymoma or thymic carcinoma). We hope to learn whether this drug is an effective and safe treatment for thymic cancers.
Official Title
A Phase II Study of Amrubicin in Relapsed or Refractory Thymic Malignancies
Eligibility Criteria
Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Investigator(s)
Joel Neal, MD, PhD
Medical oncologist,
Thoracic specialist
Associate Professor of Medicine (Oncology)
A. Dimitrios Colevas, MD
Medical oncologist,
Head and neck specialist,
Cutaneous oncology specialist
Professor of Medicine (Oncology) and, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS) and of Radiation Oncology (Radiation Therapy)
Contact us to find out if this trial is right for you.
CONTACT
Ccto-office@stanford.edu
(650) 498-7061
View on ClinicalTrials.gov